Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death,Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2024-08-15 , DOI: 10.1021/acs.jmedchem.4c00729
Meng Liu ₁ , Shan Gao ₁ , Yong Wang ₂ , Xinying Yang ₁ , Hao Fang ₁ , Xuben Hou ₁

Affiliation

Ferroptosis is a unique type of cell death, characterized by its reliance on iron dependency and lipid peroxidation (LPO). Consequently, small-molecule ferroptosis modulators have garnered substantial interest as a promising avenue for cancer therapy. Herein, we explored the ferroptosis sensitivity of epigenetic modulators and found that the antiproliferative effects of class I histone deacetylase (HDAC) inhibitors are significantly reliant on ferroptosis. Subsequently, we developed a novel series of HDAC inhibitors, identifying HL-5s with robust inhibitory activity against class I HDACs, particularly HDAC1. Notably, HL-5s induces ferroptosis by augmenting LPO production. Mechanistically, HL-5s increased the YB-1 acetylation and inhibited the Nrf2/HO-1 signaling pathway. Furthermore, HL-5s not only significantly suppresses tumor growth in the PC-9 xenograft model but also remodels the tumor microenvironment in the LLC allograft model. Our study has unveiled that class I HDAC inhibitors can exert antitumor effects by triggering ferroptosis, and HL-5s may serve as a promising candidate for future cancer treatment.

中文翻译：

发现一种新型苯并咪唑衍生物靶向组蛋白脱乙酰酶诱导铁死亡并引发免疫原性细胞死亡

铁死亡是一种独特的细胞死亡类型，其特点是依赖铁依赖性和脂质过氧化（LPO）。因此，小分子铁死亡调节剂作为癌症治疗的一种有前景的途径引起了人们的极大兴趣。在此，我们探索了表观遗传调节剂的铁死亡敏感性，发现 I 类组蛋白脱乙酰酶 (HDAC) 抑制剂的抗增殖作用显着依赖于铁死亡。随后，我们开发了一系列新型 HDAC 抑制剂，鉴定出HL-5对 I 类 HDAC，特别是 HDAC1 具有强大的抑制活性。值得注意的是， HL-5s通过增加 LPO 的产生来诱导铁死亡。从机制上讲， HL-5s增加 YB-1 乙酰化并抑制 Nrf2/HO-1 信号通路。此外， HL-5s不仅显着抑制PC-9异种移植模型中的肿瘤生长，而且还重塑了LLC同种异体移植模型中的肿瘤微环境。我们的研究表明，I 类 HDAC 抑制剂可以通过引发铁死亡来发挥抗肿瘤作用，而HL-5可能成为未来癌症治疗的有希望的候选者。

更新日期：2024-08-15

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南